ASX · CSL.AX
CSL Limited
A$201.59+A$4.09 (+2.07%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.26% below the high.
Loading market information…
ASX · OIL.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 12:38 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Optiscan Imaging Limited’s quoted price sits in the upper half of its reported 52-week range, 22.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Optiscan Imaging Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Optiscan Imaging Limited specializes in the development and market introduction of confocal microscopy technology, applied across both clinical and pre-clinical settings in Australia, Germany, and other global regions. A notable offering is the FIVE2 (ViewnVivo) system, a compact confocal endomicroscope utilized for a broad range of research, including clinical, translational, and pre-clinical studies. Additionally, the company is actively developing the InVivage device, which is intended for use in cancer screening and surgical procedures. Established in 1994, Optiscan Imaging Limited maintains its headquarters in Mulgrave, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$201.59+A$4.09 (+2.07%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.26% below the high.
A$2.75+A$0.03 (+1.1%)
Sigma Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 14.06% below the high.
A$198.95+A$1.86 (+0.94%)
Pro Medicus Limited’s quoted price sits in the upper half of its reported 52-week range, 27.08% below the high.
A$3.03-A$0.25 (-7.48%)
4DMedical Limited’s quoted price sits in the lower half of its reported 52-week range, 59.87% below the high.
A$1.50A$0.00 (0.0%)
EMVision Medical Devices Ltd’s quoted price sits in the lower half of its reported 52-week range, 23.47% below the high.
A$0.24+A$0.01 (+2.17%)
Compumedics Limited’s quoted price sits in the lower half of its reported 52-week range, 47.78% below the high.
A$0.04-A$0.00 (-5.13%)
Micro-X Limited’s quoted price sits in the lower half of its reported 52-week range, 67.83% below the high.
A$0.01A$0.00 (0.0%)
Imagion Biosystems Limited’s quoted price sits in the lower half of its reported 52-week range, 85.71% below the high.
